Advancements in Bispecific Antibody Therapies: Recent Deals and Clinical Data on VEGF-Targeting Agents

Efdamrofusp Alfa (IBI302):
A bispecific fusion protein targeting both VEGF and C3b/C4b has shown superior efficacy over anti-VEGF monotherapy in preclinical models and favorable safety profiles in a phase 1 clinical trial for nAMD.

Glofitamab:
A bispecific antibody targeting CD20 and CD3 is being developed for B-cell non-Hodgkin’s lymphoma and has demonstrated promising data in phase II studies. Biogen will receive tiered royalties on potential net sales within the United States.

PM8002:
A bispecific antibody candidate targeting PD-L1 and VEGF-A has shown encouraging antitumor activity and a positive safety profile. BioNTech will develop and commercialize PM8002 globally, excluding Greater China, under a license agreement with Biotheus.

Ivonescimab (PD-1/VEGF):
Akeso Inc. has entered a collaboration and license agreement with Summit Therapeutics for up to $5 billion to accelerate global development and commercialization of ivonescimab, a breakthrough bispecific antibody combining PD-1 blockade with anti-VEGF benefits.

Bispecific Antibodies in Retina Therapies:
Various bispecific antibodies, such as faricimab (VEGF-A and Ang2), AG-73305 (VEGF and integrins), and BI 836880 (VEGF and Ang2), are being developed and studied for the treatment of nAMD, DME, and other retinal diseases.